Johnson & Johnson (NYSE:JNJ) Shares Sold by OneDigital Investment Advisors LLC

OneDigital Investment Advisors LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 86,508 shares of the company’s stock after selling 3,735 shares during the quarter. OneDigital Investment Advisors LLC’s holdings in Johnson & Johnson were worth $12,511,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. IFS Advisors LLC boosted its stake in shares of Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after acquiring an additional 100 shares in the last quarter. WealthTrak Capital Management LLC purchased a new stake in Johnson & Johnson during the fourth quarter worth $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in Johnson & Johnson in the fourth quarter valued at $29,000. Bay Harbor Wealth Management LLC purchased a new position in shares of Johnson & Johnson in the fourth quarter valued at $32,000. Finally, Conquis Financial LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth $33,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Trading Down 0.3 %

Shares of JNJ stock opened at $157.00 on Tuesday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The firm’s 50 day moving average price is $159.53 and its two-hundred day moving average price is $154.93. The stock has a market cap of $378.35 billion, a price-to-earnings ratio of 23.61, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $21.89 billion during the quarter, compared to analysts’ expectations of $21.65 billion. On average, analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.31%. The ex-dividend date is Tuesday, May 27th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s dividend payout ratio is currently 57.84%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on JNJ shares. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their target price for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Argus raised Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Wells Fargo & Company cut their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Stifel Nicolaus reduced their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a report on Thursday, January 23rd. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $171.82.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.